heparinoid


Also found in: Dictionary, Thesaurus, Encyclopedia, Wikipedia.

heparinoid

(hĕp-ah-rin-oyd'),
A general term used for substances with activity similar to heparin; an, anticoagulant.

heparinoid

(hĕp′ă-rĭ-noyd″)
A substance that prevents or treats blood clots. Heparinoids have a lower risk for bleeding and thrombocytopenia than heparin.

heparinoid

; Lasonil topical heparin analogue (0.3-0.8% cream or gel) used to disperse severe bruising and haematoma
References in periodicals archive ?
a heparinoid for thromboembolic diseases, and Parnaparin (FLUXUM[sup.
Based on this finding, we recommend that in a bleeding patient with a TEG picture consistent with an endogenous heparinoid effect who is not responding to standard therapy, protamine sulphate administration could be considered.
Danaparoid, a low-molecular-weight heparinoid with low placental permeability, is considered by some to be the drug of choice for heparin allergy in pregnancy, (12,17-19) but is currently not available in South Africa and was therefore not an option in this patient.
The three available LMWH products, dalteparin (Fragmin), enoxaparin (Lovenox), and tinzaparin (Innohep), and a low-molecular-weight heparinoid, danaparoid, are rated B, because animal reproduction studies have found no evidence of fetal harm.
Heparinex's core platforms employ both bacterial production techniques and in vitro defined polymer syntheses to provide uniquely controlled non-animal sources of genetically customizable heparinoid compounds for drug discovery, therapeutic formulations and medical device applications.
Alfa Wassermann has also developed other important products: Sulodexide (VESSEL), a heparinoid for thromboembolic diseases, and Parnaparin (FLUXUM), a low molecular weight heparin for the treatment and prophylaxis of deep-vein thrombosis.
Keryx's lead compound under development is Sulonex(TM) (sulodexide) oral gelcaps, previously referred to as KRX-101, a first-in-class, oral heparinoid compound for the treatment of diabetic nephropathy, a life-threatening kidney disease caused by diabetes.
Keryx's lead compound under development is Sulonex(TM) (sulodexide oral gelcap), previously referred to as KRX-101, a first-in-class, oral heparinoid compound for the treatment of diabetic nephropathy, a life-threatening kidney disease caused by diabetes.
Heparinex's core platforms employ (a) bacterial production techniques and (b) in vitro defined polymer syntheses to provide uniquely controlled non-animal sources of genetically customizable heparinoid compounds for drug discovery, therapeutic formulations and medical device applications.
Keryx is developing KRX-101 (sulodexide), a novel first-in-class oral heparinoid compound, for the treatment of diabetic nephropathy, for which Keryx recently commenced its U.
Our lead compound under development is Sulonex(TM) (sulodexide), which we previously referred to as KRX-101, a first-in-class, oral heparinoid compound for the treatment of diabetic nephropathy, a life-threatening kidney disease caused by diabetes.
Under the new agreement, Progen will contribute $2 million during the next three years for research into synthesis of heparinoid mimetics and the development of the heparanase enzyme for diagnostic and therapeutic purposes.